FindTrial
Sign In

indium In 111 anti-CD45 monoclonal antibody BC8

BIOLOGICAL2 trials

Sponsors

Fred Hutchinson Cancer Center

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaChronic Myelomonocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular Lymphoma

Phase 1

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
CompletedNCT01300572
Fred Hutchinson Cancer CenterChronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia +3
Start: 2012-01-31End: 2019-11-22Updated: 2019-12-10
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
TerminatedNCT01678443
Fred Hutchinson Cancer CenterAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma +30
Start: 1999-09-01End: 2018-09-27Updated: 2021-04-02

Related Papers

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
Haematologica2019-10-0329 citations
Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)
Blood2018-11-298 citations